There were 522 press releases posted in the last 24 hours and 185,331 in the last 365 days.

Brain Tumor Drugs Market To Include Immunological Approaches Like Cell/Gene Therapy For Better Treatment As Per TBRC's Global Brain Tumor Drugs Market Report

This report describes and evaluates the global brain tumor drugs market. It covers three five years’ periods, including 2015 to 2020, termed the historic period, 2020 – 2025 forecast period and 2025 – 2030 a further forecast period.

/EIN News/ -- LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- According to The Business Research Company’s research report on the brain tumor drugs market, cell and gene therapies are expected to be available with more variety according to the Food and Drug Administration (FDA) of the United States. The FDA also stated that by 2025, the organization is affirmative to approve up to 20 cell and gene therapies of around 300 currently in development. Recent progress in immunotherapy, across a broad range of tumor types, provides hope that immunological approaches will have the potential to improve outcomes for patients with brain tumors.

For instance, in May 2021, scientists in Australia have used chimeric antigen receptor (CAR) T cell therapy to clear brain cancer tumors in preclinical models. Their study named “Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma” was published in Clinical and Translational Immunology, and the scientists believes that this approach to immunotherapy design could pave the way for new treatments for people with glioblastoma.

The global brain tumor drugs market size is expected to grow from $1.89 billion in 2020 to $2.01 billion in 2021 at a compound annual growth rate (CAGR) of 6.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.89 billion in 2025 at a CAGR of 9.5%.

Asia Pacific was the largest region in the brain tumor drugs market, accounting for 31.8% of the total in 2020. It was followed by the North America, Western Europe and then the other regions. Going forward, the fastest-growing regions in the brain tumor drugs market will be Asia Pacific and Western Europe where growth will be at CAGRs of 11.8% and 9.9% respectively during 2020-2025. These will be followed by South America and North America, where the markets are expected to register CAGRs of 9.4% and 9.1% respectively during 2020-2025.

The Business Research Company’s report titled Global Brain Tumor Drugs Market Report 2021 - By Drugs (Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib), By End User (Hospital Pharmacies, Clinics), COVID-19 Impact And Recovery covers major brain tumor drugs companies, brain tumor drugs market share by company, brain tumor drugs manufacturers, brain tumor drugs market size, and brain tumor drugs market forecasts. The report also covers the global brain tumor drugs market and its segments.

Request For A Sample Of The Global Brain Tumor Drugs Market Report:

Companies in the brain tumor drugs market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive brain tumor drugs market, companies are developing innovative products as well as sharing skills and expertise with other companies. For instance, in 2020, Century Therapeutics, a US based biotechnology company developing curative therapies for cancer announced the acquisition of Empirica Therapeutics, for an undisclosed amount. Under this deal, Century aims to develop induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies against the brain cancer glioblastoma.

The global brain tumor drugs market is fragmented, with a large number of players. The top ten competitors in the market made up to 28.1% of the total market in 2020. Major players in the market include F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., and Merck & Co. Inc.

Player-adopted strategies in the brain tumor drugs market include focusing on new product development, strategic collaborations, expanding business presence in developed and emerging regions, strategic acquisitions and agreements, and strengthening their product portfolio by new drug approvals.

Brain Tumor Drugs Global Market Report 2021 COVID-19 Impact And Recovery is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, segments and geographies, trends, drivers, restraints, leading competitors’ revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports By The Business Research Company:

Oncology Drugs Global Market Report 2021 - By Type (Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), COVID-19 Impact And Recovery

Brain And Neuroimaging Devices Global Market Report 2021 - By Imaging Type (Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG)), By End-User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), By Application (Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders), COVID-19 Growth And Change

Tumor Ablation Therapy Devices Global Market Report 2021 - By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation), By Treatment (Surgical, Laparoscopic, Percutaneous), By End User (Hospitals, Oncology Clinics), By Application (Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer), COVID-19 Growth And Change

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Get a quick glimpse of our services here:

The World’s Most Comprehensive Database

The Business Research Company’s flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.


The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293


Follow us on LinkedIn:

Follow us on Twitter:

Check out our Blog:

Primary Logo